title: Treatment of Parkinson's disease with the partial dopamine agonist EMD 49980.
abstract: The motor effects of the partial dopamine agonist EMD 49980 were evaluated in parkinsonian patients under controlled conditions. EMD 49980 monotherapy resulted in a mild improvement in parkinsonian symptoms, but when co-administered with levodopa, had no significant effect on dyskinesias or on the antiparkinsonian effect of the dopamine precursor. These results suggest that EMD 49980 exerts a net weak dopamine agonist effect but fails to ameliorate levodopa-induced dyskinesias.
authors.affiliation: Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892.
authors.forename: D
authors.initials: D
authors.lastname: Bravi
authors.forename: T L
authors.initials: TL
authors.lastname: Davis
authors.forename: M M
authors.initials: MM
authors.lastname: Mouradian
authors.forename: T N
authors.initials: TN
authors.lastname: Chase
mesh_terms: D000328:Adult; D001921:Brain / Q000187:drug effects / Q000503:physiopathology; D015259:Dopamine Agents / Q000627:therapeutic use*; D004311:Double-Blind Method; D004409:Dyskinesia, Drug-Induced / Q000188:drug therapy / Q000503:physiopathology; D005260:Female; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D007980:Levodopa / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009460:Neurologic Examination / Q000187:drug effects; D000078183:Oxindoles; D010300:Parkinson Disease / Q000188:drug therapy* / Q000503:physiopathology; D011725:Pyridines / Q000627:therapeutic use*; D011954:Receptors, Dopamine / Q000187:drug effects* / Q000502:physiology
chemical_list: D015259:Dopamine Agents; D007211:Indoles; D000078183:Oxindoles; D011725:Pyridines; D011954:Receptors, Dopamine; C059613:roxindole; D007980:Levodopa